{"paper_id":"59e2dfb6-5392-47b3-bae3-9765eb4a7ef4","body_text":"Abstract\nPurpose\nTo summarize evidence on levonorgestrel releasing intrauterine system (LNG–IUS) in the treatment of adenomyosis (AM) and to identify potential research gaps.\nMethods\nSearch was conducted in MEDLINE, The Cochrane Library, EMBASE, CBM, CNKI, and Wanfang. We included studies investigating patients with AM treated with LNG–IUS combined with conservative therapy.\nResults\nThirty-nine studies compared LNG–IUS with other conservative therapeutic drugs. The most common comparison was GnRH-a + LNG–IUS vs. LNG–IUS alone, followed by LNG–IUS vs. mifepristone, expected treatment, and GnRH-a. GnRH-a + LNG–IUS was more beneficial in reducing the intensity of dysmenorrhea than LNG–IUS alone at the 6-month follow-up in patients with an enlarged uterus and moderate to severe dysmenorrhea. Large and well-designed studies are needed to confirm the efficacy of LNG–IUS and GnRH-a on reducing uterine volume at 6-month follow-up. Thirty-two studies investigated LNG–IUS as the postoperative management. The most common comparison was surgical excision + LNG–IUS vs. surgical excision. Results showed VAS scores were lower in the surgical excision + LNG–IUS group than in the surgical excision group at the 1-year follow-up. Evidence on endometrial thickness, quality of life, adverse events and beneficial effect at 3 and 5 years are needed.\nConclusions\nCombined GnRH-a and LNG–IUS treatment was more efficacious than LNG–IUS alone for patients with an enlarged uterus and moderate to severe dysmenorrhea. Moreover, LNG–IUS seemed to show potential long-term benefits in postoperative therapy, warranting further meta-analysis for confirmation.\nSimilar content being viewed by others\nData availability\nThe data that support the findings of this study are available on request from the corresponding author.\nAbbreviations\n- LNG–IUS:\n-\nLevonorgestrel releasing intrauterine system\n- AM:\n-\nAdenomyosis\n- NSAIDs:\n-\nNonsteroidal anti-inflammatory drugs\n- GnRH-a:\n-\nGonadotropin-releasing hormone agonists\n- RRs:\n-\nRisk ratios\n- Cis:\n-\nConfidence intervals\n- MDs:\n-\nMean differences\n- VAS:\n-\nVisual analogue scale\n- PBAC:\n-\nPictorial blood loss assessment chart\n- COC:\n-\nCombined oral contraceptive\n- FUA:\n-\nFocused ultrasound ablation\n- UFS–QOL:\n-\nUterine Fibroid Symptom and Health-related Quality Of Life questionnaire\nReferences\nStruble J, Reid S, Bedaiwy M (2016) Adenomyosis: a clinical review of a challenging gynecologic condition. J Minim Invasive Gynecol 23:164–185. https://doi.org/10.1016/j.jmig.2015.09.018\nLeng J (2020) Expert consensus on diagnosis and treatment of adenomyosis in China. Chin J Obstet Gynecol 55:376–383\nCulley L, Law C, Hudson N, Denny E, Mitchell H, Baumgarten M et al (2013) The social and psychological impact of endometriosis on women’s lives: a critical narrative review. Hum Reprod Update 19:625–639. https://doi.org/10.1093/humupd/dmt027\nTaran FA, Stewart EA, Brucker S (2013) Adenomyosis: epidemiology, risk factors, clinical phenotype and surgical and interventional alternatives to hysterectomy. Geburtshilfe Frauenheilkd 73:924–931. https://doi.org/10.1055/s-0033-1350840\nGarcia L, Isaacson K (2011) Adenomyosis: review of the literature. J Minim Invasive Gynecol 18:428–437. https://doi.org/10.1016/j.jmig.2011.04.004\nGambone JC, Mittman BS, Munro MG, Scialli AR, Winkel CA, Group CPPEW (2002) Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process. Fertil Steril 78:961–972. https://doi.org/10.1016/s0015-0282(02)04216-4\nFraser IS (2013) Added health benefits of the levonorgestrel contraceptive intrauterine system and other hormonal contraceptive delivery systems. Contraception 87:273. https://doi.org/10.1016/j.contraception.2012.08.039\nDueholm M (2018) Minimally invasive treatment of adenomyosis. Best Pract Res Clin Obstet Gynaecol 51:119–137. https://doi.org/10.1016/j.bpobgyn.2018.01.016\nImai A, Matsunami K, Takagi H, Ichigo S (2014) Levonorgestrel-releasing intrauterine device used for dysmenorrhea: five-year literature review. Clin Exp Obstet Gynecol 41:495–498. https://doi.org/10.12891/ceog17042014\nLi L, Leng J, Jia S, Lang J (2019) Treatment of symptomatic adenomyosis with the levonorgestrel-releasing intrauterine system. Int J Gynecol Obstet 146:357–363. https://doi.org/10.1002/ijgo.12887\nTrussell J, Hassan F, Henry N, Pocoski J, Law A, Filonenko A (2014) Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in contraception. Contraception 89:451–459. https://doi.org/10.1016/j.contraception.2013.10.019\nFraser IS (2010) Non-contraceptive health benefits of intrauterine hormonal systems. Contraception 82:396–403. https://doi.org/10.1016/j.contraception.2010.05.005\nUysal A, Taner CE, Mun S, Uysal F, Celimli FHJJPMA (2013) Use of a levonorgestrel-releasing intrauterine device in the treatment of adenomyosis associated heavy menstrual bleeding. J Pak Med Assoc 63:1349–1352. https://doi.org/10.1007/s00109-013-1059-4\nHealth NIf, Excellence C (2019) Heavy menstrual bleeding: assessment and management. National Institute for Health and Care Excellence (NICE)\nPractice Bulletin No. 136: Management of Abnormal Uterine Bleeding Associated With Ovulatory Dysfunction (2013) Obstet Gynecol (New York 1953) 122:176–185. https://doi.org/10.1097/01.AOG.0000431815.52679.bb\nSingh S, Best C, Dunn S, Leyland N, Wolfman WL (2018) No. 292-abnormal uterine bleeding in pre-menopausal women. J Obstet Gynaecol Can 40:e391–e415. https://doi.org/10.1016/j.jogc.2018.03.007\nEkin M, Cengiz H, Ayağ ME, Kaya C, Yasar L, Savan K et al (2013) Effects of the levonorgestrel-releasing intrauterine system on urinary symptoms in patients with adenomyosis. Eur J Obstet 170:517–520. https://doi.org/10.1016/j.ejogrb.2013.07.019\nAbbas AM, Samy A, Atwa K, Ghoneim HM, Lotfy M, Saber Mohammed H et al (2020) The role of levonorgestrel intra-uterine system in the management of adenomyosis: a systematic review and meta-analysis of prospective studies. Acta Obstet Gynecol Scand 99:571–581. https://doi.org/10.1111/aogs.13798\nTricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169:467–473. https://doi.org/10.7326/M18-0850\nHiggins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al (2011) The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. Bmj 343. https://doi.org/10.1136/bmj.d5928\nWells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M et al (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford\nLi QY, Liu RX, Feng ZY (2015) Treatment of 49 cases of adenomyosis with leuprorelin combined with manyuele. China Pharm 24:85–86\nTian Y, Ran L, Gu X, Ke FM, Shui CY (2020) Evaluation of clinical effect of Mirena combined with leuprolide in the treatment of adenomyosis complicated with ovarian endometrioma. Mod Dig Interv (S01): 0294-0294\nLi GH, Wang FQ, Li XF, Li XH (2016) To observe the curative effect of GnRHa combined with levonorgestrel-releasing intrauterine system in the treatment of severe large uterine adenomyosis. J Int Obstet Gynecol 43:594–597\nLi Y, Ding J, Zhao CM (2018) Clinical study of Marvelon combined with and without Mirena in the treatment of adenomyosis. Med J West China 30:716–719. https://doi.org/10.3969/j.issn.1672-3511.2018.05.022\nTu L, Cao HB, Wu HH (2012) Comparison of the elficacy of LNG-IUS and GnRHa. n the treatment with adenomyosis. Shandong Med J 52:7–9. https://doi.org/10.3969/j.issn.1002-266X.2012.30.003\nWu Y, Ge JL, Ning Y (2020) Effect of gonadotropin—releasing hormone agonist versus leV0norgestrel releasing intrauterine system in the treatment of adenomyosis. J Clin Med Pract 24:83–86\nShaaban OM, Ali MK, Sabra AMA, Abd El Aal DEM (2015) Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial. Contraception 92:301–307. https://doi.org/10.1016/j.contraception.2015.05.015\nWang QZ, Wu XF, He L (2015) Analysis of the therapeutic effect of levonorgestrel intrauterine sustained-release system on adenomyosis. Hebei Med 21:805–807. https://doi.org/10.3969/j.issn.1006-6233.2015.05.033\nMao JJ, Zheng MN, Hu BZ (2017) Efficacy analysis of levonorgestrel intrauterine sustained release system in the treatment of patients with adenomyosis. Chin J Clin Pharmacol Ther 22:1158–1161\nTu J, Gao Y, Huang ML, Xiao YB (2016) Influence of levonorgestrel—releasing intrauterine system on menstruation and ovarian function of patients with adenomyosis of uteru. Chin Gen Pract 19:427–430. https://doi.org/10.3969/j.issn.1007-9572.2016.04.014\nZhang DY, Guo HJ, Qiu HF (2019) Effects of GnRH-α combined with mirena and serum recurrence related indicators in patients with adeno⁃ myosis. J Pract Med 35:84–87. https://doi.org/10.3969/j.issn.1006-5725.2019.01.018\nWang LJ, Tang CH (2021) Influence of GnRH—n combined with levonorgestrel intrauterine device system for treating women with adenomyosis on their pain symptoms,serum MMPs level, and recurrence rate. Chin J Fam Plan Gynecotokol 29:266–70+74. https://doi.org/10.3969/j.issn.1004-8189.2021.02.014\nQin WL, Liao JJ (2019) Effects of triptorelin acetate injection combined with levonorgestrel-releasing intra-uterine system on uterine hemodynamics, ovarian function and safety in patients with adenomyosis of uterus. Eval Anal Drug Use Hosp China 19:546–8+51\nGuo MH, Deng ZM, Xu H (2020) Clinical study of Mirena combined with gonadotropin—releasing hormone agonist in the treatment of adenomyosis. J Guangxi Med Univ 37:506–509\nLuo YM, Li q, Mai Y, Li XP, Zhang M (2017) Clinical observation of goserelin in the treatment of adenomyosis complicated with severe dysmenorrhea before placing levonorgestrel intrauterine system. China Pharm 28:3671–4. https://doi.org/10.6039/j.issn.1001-0408.2017.26.20\nFeng HP, Zhao SJ, Tang Y (2019) Curative efficacy of levonorgestrel sustained release system combined with triptorelin in treatment of adenomyosis of the uterus and its effect on serum CA125 CA199 and HE. Hebei Med 25. https://doi.org/10.3969/j.issn.1006-6233.2019.01.001\nWang HL, Fan XF, Zhang LF (2018) Efficacy of major uterine wall resection-reconstruction of the uterus combined with mirena in the treatment of moderate and severe adenomyosis and the effects on ovarian function. Anhui Med Pharm J 22:2375–2378. https://doi.org/10.3969/j.issn.1009-6469.2018.12.026\nWu ZY, Pan ZX, Lv XP, Du YY, Jing MJ (2018) Clinical observation of high intensity focused ultrasound combined with levonorgestrel intrauterine sustained release system in the treatment of adenomyosis. Shandong Med J 58:65–67. https://doi.org/10.3969/j.issn.1002-266X.2018.03.020\nIndex of the key magazine of China technology (2021) https://www.zzqklm.com/w/hxml/29764.html\nWang Q (2014) The clinical application of levonorgestrel·releasing intrauterine system oil the treatment of clinical analysis of adenomyosis. Clin Med China 30:775–777. https://doi.org/10.3760/cma.j.issn.1008-6315.2014.07.038\nWang QY, Zhang H, Liu ZZ (2016) Study on the influence of Mirena treatment for the uterine b ood flow dynamics and serum related indexes of patients with uterine ac denomyosis. J Hainan Med Univ 22:1973–1975. https://doi.org/10.13210/j.cnki.jhmu.20160602.004\nYu LX, Xu L (2019) Effects of high intensity focused ultrasound combined with levonorgestrel intrauterine sustained release system on serum CA 125, anti endometrial antibody, hemoglobin and ovarian function in patients with adenomyosis. Fam Plan Obstet Gynecol China 11:33–36\nChen FQ, Wang AP, Zhang AF, Wang XB (2013) Clinical analysis of hysteroscopic transcervical resection of endometrium with levonorgestrel-releasing intrauterine system in treatment of adenomyosis. J Shanghai Jiaotong Univ (Med Sci) 33:1098–1102. https://doi.org/10.3969/j.issn.1674-8115.2013.08.012\nChen FQ, Zhang AF, Wang XB (2017) Prospective study of the treatment of adenomyosis by combining hysteroscopic transcervical resection of endometrium with levonorgestrel-releasing intrauterine system. J Shanghai Jiaotong Univ (Med Sci) 37:641–645. https://doi.org/10.3969/j.issn.1674-8115.2017.05.014\nSun HB (2013) Transcervical resection of endometrium combined with levonorgestrel releasing intrauterine system treatment for 45 patients with adenomyosis. J Reg Anat Oper Surg 22:431–432. https://doi.org/10.11659/jjssx.1672-5042.201304035\nOzdegirmenci O, Kayikcioglu F, Akgul MA, Kaplan M, Karcaaltincaba M, Haberal A et al (2011) Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril 95:497–502. https://doi.org/10.1016/j.fertnstert.2010.10.009\nLi QY, Du LF, Xie CQ, Chen X (2017) Comparative study of clinical effect of Mirena and uterine wedge resection in the treatment of adenomyosis. Chin Med Innov 14:56–58. https://doi.org/10.3969/j.issn.1674-4985.2017.27.016\nZheng J, Xia E, Li TC, Sun X (2013) Comparison of combined transcervical resection of the endometrium and levonorgestrel-containing intrauterine system treatment versus levonorgestrel-containing intrauterine system treatment alone in women with adenomyosis: a prospective clinical trial. J Reprod Med 58:285–290\nYe MZ, Deng XL, Zhu XG, Xue M (2016) Clinical study of high intensity focused ultrasound ablation combined with GnRH-a and LNG-IUS for the treatment of adenomyosis. Zhonghua Fu Chan Ke Za Zhi 51:643–649. https://doi.org/10.3760/cma.j.issn.0529-567X.2016.09.002\nXu F, Wei YZ, Meng TY, Guo Q (2020) Clinical study of intensity focused ultrasound combined with levonorgestrel intrauterine sustained-release system in the treatment of adenomyosis. J Chin Phys 22:1185–8+-8,93. https://doi.org/10.3969/j.issn.1002-266X.2018.03.020\nGuo Q, Xu F, Ding Z, Li P, Wang X, Gao B (2018) High intensity focused ultrasound treatment of adenomyosis: a comparative study. Int J Hyperth 35:505–509. https://doi.org/10.1080/02656736.2018.1509238\nZhao DX, Zhang Y (2016) EmctS of different treatment methods on the quaIity of sexual life and marital life of patients with adenomy. Chin J Hum Sex 25:43–46\nDing HY, Han Y (2017) Effects of three treatment methods on sexual function of patients with adenomyosis. Chin Sex Sci 26:48–51. https://doi.org/10.3969/j.issn.1672-1993.2017.08.015\nZhang CW, Deng SL (2018) The effect observation of postoperative use of levonorgestrel slow releasing system in the vagina on adenomyosis patients after laparoscopic uterus wedge resection. Chin J Hum Sex 27:106–108. https://doi.org/10.3969/j.issn.1672-1993.2018.04.033\nWang XY, Han X (2019) Comparative study on treatment of adenomyosis with adenomyotomy combined with mirenaor GnRH-a. J Med Res 48:148–51+56. https://doi.org/10.3785/j.issn.1008-9292.2019.04.03\nZhao R, Gu YC, Wang LM, Chen Y, Wei TM, Wang SM (2016) Effect of laparoscopic cuneiform hysterectomy combined with postoperative vaginal placement of manyuele in the treatment of adenomyosis. Shandong Med J 56:52–54. https://doi.org/10.3969/j.issn.1002-266X.2016.07.019\nWu Q, Lian Y, Chen L, Yu Y, Lin T (2020) Alleviation of symptoms and improvement of endometrial receptivity following laparoscopic adenomyoma excision and secondary therapy with the levonorgestrel-releasing intrauterine system. Reprod Sci (Thousand Oaks, CA) 27:1259–1265. https://doi.org/10.1007/s43032-019-00130-4\nYang F (2017) Effect of intrauterine and progesterone sustained—release system assisted ablation on estrogen and progesterone receptor expression in patients with adenomyosis. J Med Res 46:164–7+3. https://doi.org/10.11969/j.issn.1673-548X.2017.07.041\nLi DH, Xu YY, Shou J, Lin F, Zhang M, Shen QF (2010) Observation of 53 cases of uterine adenomyosis pain treated by laparoscopic adenomyoma lesion resection combined with Mirena. Chin J Crit Care Med (Electron Ed) 3:331–334. https://doi.org/10.3877/cma.j.issn.1674-6880.2010.05.011\nLin C-J, Hsu T-F, Chang Y-H, Huang B-S, Jiang L-Y, Wang P-H et al (2018) Postoperative maintenance levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyoma. Taiwan J Obstet Gynecol 57:47–51. https://doi.org/10.1016/j.tjog.2017.12.036\nLi Q, Yuan M, Li N, Zhen Q, Chen C, Wang G (2020) The efficacy of medical treatment for adenomyosis after adenomyomectomy. J Obstet Gynaecol Res 46:2092–2099. https://doi.org/10.1111/jog.14376\nXu Y, Zhou Z, Wang H, Shao L, Liu G (2021) High-intensity focused ultrasound combined with gonadotropin-releasing hormone agonist or levonorgestrel-releasing intrauterine system in treating dysmenorrhea of severe adenomyosis. J Comput Assist Tomogr 45:224–231. https://doi.org/10.1097/RCT.0000000000001138\nWen J, M, Zhu AY, Feng LL, Li XA (2012) Radiofrequency ablation combined with levonorgestrel-releasing intrauterine system in treatment of adenomyosis. Clin Misdiagn Misther 25:91–3. https://doi.org/10.3969/j.issn.1002-3429.2012.09.041\nLei QH, Gong CM, Li LQ, Diao FY (2014) Clinical analysis of uterine function reserved major uterine wall resection combined with mirena for severe adenomyosis. China J Mod Med 24:82–84. https://doi.org/10.3969/j.issn.1005-8982.2014.16.020\nYang H, Liang ZY (2014) Comparison of short-term efficacy of two conservative treatment methods for adenomyosis. Chin J Fam Plan Gynecotokol 22:678–681. https://doi.org/10.3969/j.issn.1004-8189.2014.10\nLiu XP, Zhang YP, Yang RG, Yan CX, Bai JH, Zhou GP et al (2012) Clinical study on the effect of different treatment methods on the quality of life of patients with adenomyosis. Clin J Med Off 40:226–228. https://doi.org/10.3969/j.issn.1671-3826.2012.01.090\nMaia H Jr, Maltez A, Coelho G, Athayde C, Coutinho EM (2003) Insertion of mirena after endometrial resection in patients with adenomyosis. J Am Assoc Gynecol Laparosc 10:512–516. https://doi.org/10.1016/s1074-3804(05)60158-2\nLou J, Huang X, Zhang L, Xu P, Zhang X, Chen Z (2019) The second generation endometrial ablation (NovaSure) improves efficacy of levonorgestrel-releasing intrauterine system in management of adenomyosis. Zhejiang da xue xue bao Yi xue ban J Zhejiang Univ Med Sci 48:136–41. https://doi.org/10.3785/j.issn.1008-9292.2019.04.03\nLi X, Zhu X, He S, Jiang Z, Li H, Tian X et al (2021) High-intensity focused ultrasound in the management of adenomyosis: long-term results from a single center. Int J Hyperth 38:241–247. https://doi.org/10.1080/02656736.2021.1886347\nLiu XD, Lin H, Wu SZ, Chen CY (2015) Clinical observation on hysteroscopic transcervical resection of endometrium combined with levonorgestrel-releasing intrauterine system in treatment of adenomyosis. J Reg Anat Oper Surg 24:195–197\nLi Q, Ding Y, Zhang X-Y, Feng W-W, Hua K-Q (2018) Drug therapy for adenomyosis: a prospective, nonrandomized, parallel-controlled study. J Int Med Res 46:1855–1865. https://doi.org/10.1177/0300060517752997\nXu LM, Chen HT, Zhao Y, Lv JQ (2019) The efficacy of GnRH-a combined with drospironone and ethinylestradiol tablets for treating women with adenomyosis and its effect on tumor markers. Chin J Fam Plan Gynecotokol 27:776–779\nYao B, Zhu Y, Quan XZ (2014) Clinical comparison of the effects of IUD placement and drug therapy on the quality of sexual life in patients with adenomyosis. Chin J Hum Sex 23:34–37. https://doi.org/10.3969/j.issn.1672-1993.2014.10.010\nJiang YP, Zhang QD, Wang CP, Wan SQ, Yin XG (2017) Effect of levonorgestrel releasing intrauterine system and small dose of mifepristone in the treatment of adenomyosis. Chin Gen Pract 20:111–113. https://doi.org/10.3969/j.issn.1007-9572.2017.z1.039\nFang F, Liu SP, Wang XJ, Lin XL (2015) Selection of grading scheme for conservative treatment of adenomyosis. Shanghai Med J 38:239–244\nZhang Y (2017) Effects of gonadotropin-releasing hormone agonists on adenomyosis complicated with severe dysmenorrhea and menstrual volume before placement of levonorgestrel intrauterine sustained-release system. Anhui Med Pharm J 21:1311–1313. https://doi.org/10.3969/j.issn.1009-6469.2017.07.039\nZhou YP, Wu XY, Dong QY, Huang MJ (2013) GnRH-a combined with levonorgestrel intrauterine sustained release system in the treatment of adenomyosis in rats. Chin J Minim Invasive Surg 13:1002–4+11\nLi L, Leng JH, Jia SZ, Zhang JJ, Li XY, Shi JH et al (2016) Impact of pre-treatment with GnRHa on the effects of LNG-IUS for symptomatic adenomyosis. Prog Obstet Gynecol 25:337–41. https://doi.org/10.13283/j.cnki.xdfckjz.2016.05.005\nSong N, Leng JH (2009) The clinical observation of levonorgestrel intrauterine system in treatment of adenomyosis. J Reprod Med 18:508–512. https://doi.org/10.3969/j.issn.1004-3845.2009.06.002\nJin CH, Lu CY, Zhao X (2017) Clinical observation of placement of manyuele or manyuele combined with gonadotropin-releasing hormone agonist in the treatment of adenomyosis after laparoscopic resection of adenomyosis. Shanghai Med J 40:589–592\nXiao D, Fu Y, Meng Q (2020) Effects of levonorgestrel-releasing intrauterine system for dysmenorrhea patients wiith adenomyosis. J Clin Med Pract 24(15):51–54. https://doi.org/10.7619/jcmp.202015014\nDeng SZ (2014) Clinical observation of Mirena intrauterine device in the treatment of adenomyosis. Chin J Fam Plann Gynecotokol 6:42–44. https://doi.org/10.3969/j.issn.1674-4020.2014.05.13\nJiang Y, Lou HY (2013) 40 cases of uterine adenomyosis treated with levonorgestrel intrauterine sustained release system. Chin J Clin Healthc 16:314–315. https://doi.org/10.3969/J.issn.1672-6790.2013.03.035\nLiu YP, Huang JY, Huang YM, Xie BL (2020) Clinical efficacy of single subcutaneous etonogestrel implants for treatment of symptomatic adenomyosis. Guangxi Med J 42:801–804\nMao H (2013) Mirena in treatment of 54 patients with adenomyosis. Med Pharm J Chin People’s Lib Army 25:67–69. https://doi.org/10.3969/j.issn.2095-140X.2013.09.018\nWang HL (2011) Intrauterine sustained-release system of levonorgestrel in the treatment of adenomyosis. Chin J Obst Gynecol Pediatr (Electron Ed) 7:588–589. https://doi.org/10.3877/cma.j.issn.1673-5250.2011.06.020\nCho S, Choi YS, Yun BH, Chon SJ, Jung YS, Kim H et al (2015) Effects of levonorgestrel-releasing intrauterine system on lymphangiogenesis of adenomyosis. Am J Clin Pathol 143:352–361. https://doi.org/10.1309/AJCPP8F4SFYFVXRN\nYan H, Wang H, Yang LQ, Xu WJ, Pu SH (2018) Comparative study of etopotene and levonorgestrel in the treatment of adenomyosis. J Bengbu Med Coll 43:1561–1564\nQi LF, Wen YX (2016) Effect of levonorgestrel releasing intrauterine system on the treatment of adenomyosis. Chin J Hum Sex 25:29–32. https://doi.org/10.3969/j.issn.1673-0070.2008.02.007\nRathinam KK, Abraham JJ, SA S, Sen M, George MJEJoCP (2022) Evaluation of pharmacological interventions in the management of adenomyosis: a systematic review. 1–15. https://doi.org/10.1007/s00228-021-03256-0\nSong SY, Lee SY, Kim HY, Park DB, Lee KH, Lee S et al (2020) Long-term efficacy and feasibility of levonorgestrel-releasing intrauterine device use in patients with adenomyosis. J Med 99:e20421. https://doi.org/10.1097/MD.0000000000020421\nTellum T, Omtvedt M, Naftalin J, Hirsch M, Jurkovic D (2021) A systematic review of outcome reporting and outcome measures in studies investigating uterine-sparing treatment for adenomyosis. Hum Reprod Open 2021. https://doi.org/10.1093/hropen/hoab030\nAcknowledgements\nWe thank Ms. Sai Zhao and Dr. Sitong Dong for their assistance in methodology.\nFunding\nNone received.\nAuthor information\nAuthors and Affiliations\nContributions\nYD and JL contributed to the study conception and design. JS and ZG performed the literature search and study selection, XL, YW, HY, CZ and JZ performed the data extraction. ZG, XL, JS, YW and JZ performed the data summary. ZG, JL, JS and CZ prepared and wrote the manuscript. All authors were finally approval of manuscript.\nCorresponding author\nEthics declarations\nConflict of interests\nThe authors declare that they have no conflict of interest.\nAdditional information\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nSupplementary Information\nBelow is the link to the electronic supplementary material.\nRights and permissions\nSpringer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.\nAbout this article\nCite this article\nShi, J., Gu, Z., Wu, Y. et al. Long-term efficacy and safety of levonorgestrel releasing intrauterine system in the treatment of adenomyosis: evidence mapping. Arch Gynecol Obstet 310, 55–67 (2024). https://doi.org/10.1007/s00404-024-07546-7\nReceived:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-024-07546-7","source_license":"CC0","license_restricted":false}